Financhill
Sell
37

PRLD Quote, Financials, Valuation and Earnings

Last price:
$1.45
Seasonality move :
-0.12%
Day range:
$1.43 - $1.56
52-week range:
$0.61 - $4.22
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.85x
P/B ratio:
1.57x
Volume:
292.8K
Avg. volume:
2.6M
1-year change:
55.92%
Market cap:
$91.8M
Revenue:
$7M
EPS (TTM):
-$1.61

Earnings Data

Next earnings date for PRLD
Mar 17
2026
Most recent earnings per share
-$0.26
Beat by $0.10
(Nov 12/2025)
Consensus Estimate
-$0.36
(Nov 12/2025)

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

PRLD Quarterly Earnings History

Date Quarter Revenue Forecast Actual Revenue Reported EPS Consensus EPS Beat/Miss
03/17/2026 Q4 $20.5M -- -- -$0.18 --
11/12/2025 Q3 -- $6.5M -$0.26 -$0.36 $0.10
08/14/2025 Q2 -- -- -$0.41 -$0.43 $0.02
05/07/2025 Q1 -- -- -$0.42 -$0.47 $0.04
03/10/2025 Q4 -- $4M -$0.52 -$0.47 -$0.05
11/06/2024 Q3 -- $3M -$0.43 -$0.46 $0.04
08/12/2024 Q2 -- -- -$0.46 -$0.43 -$0.03
05/07/2024 Q1 -- -- -$0.42 -$0.48 $0.07
02/15/2024 Q4 -- -- -$0.60 -$0.49 -$0.11
11/01/2023 Q3 -- -- -$0.45 -$0.58 $0.13
08/03/2023 Q2 -- -- -$0.54 -- --
05/08/2023 Q1 -- -- -$0.58 -- --
03/15/2023 Q4 -- -- -$0.60 -- --
11/14/2022 Q3 -- -- -$0.63 -- --
08/09/2022 Q2 -- -- -$0.58 -- --
05/10/2022 Q1 -- -- -$0.63 -- --
03/16/2022 Q4 -- -- -$0.69 -- --
11/12/2021 Q3 -- -- -$0.65 -- --
08/12/2021 Q2 -- -- -$0.57 -- --
05/11/2021 Q1 -- -- -$0.46 -- --
03/16/2021 Q4 -- -- -$0.44 -- --
11/10/2020 Q3 -- -- -$0.38 -- --
06/30/2020 Q2 -- -- -$0.26 -- --
03/31/2020 Q1 -- -- -$0.22 -- --
12/31/2019 Q4 -- -- -$0.23 -- --
09/30/2019 Q3 -- -- -$0.15 -- --

Prelude Therapeutics, Inc. Earnings Questions

  • How Much did Prelude Therapeutics, Inc. Generate in Revenue Last Quarter?

    Prelude Therapeutics, Inc. reported $6.5M worth of top line sales in its most recent quarter.

  • Did Prelude Therapeutics, Inc. Beat Earnings Last Quarter?

    Prelude Therapeutics, Inc. announced earnings per share of -$0.26 which represents a beat of analyst forecast a -$0.36 per share.

  • Is Prelude Therapeutics, Inc. Profitable?

    Prelude Therapeutics, Inc. reported $6.1M that represents $0.08 per share over the last quarter.

  • What is the Analyst Consensus for Prelude Therapeutics, Inc. EPS Next Year?

    Prelude Therapeutics, Inc.'s earnings are forecast to decrease from -$1.68 per share to -$1.77 per share next year representing a decrease of -24.3%.

  • When is Prelude Therapeutics, Inc.'s Earnings Date?

    Prelude Therapeutics, Inc.'s next earnings date is March 17, 2026.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did SoFi Stock Drop?
Why Did SoFi Stock Drop?

Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…

Will Robinhood Win AI Investing?
Will Robinhood Win AI Investing?

Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.4T
P/E Ratio: 62x

Buy
56
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 37x

Buy
81
Is GOOG Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 40x

Alerts

Buy
56
SMX alert for Dec 6

SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.

Buy
62
PRAX alert for Dec 6

Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.

Sell
13
PSN alert for Dec 6

Parsons Corp. [PSN] is down 21.1% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock